METHODS	In this phase 3 open-label study , women with locally recurrent or metastatic breast cancer were randomly allocated ( 2:1 ) to eribulin mesilate ( 14 mg/m ( 2 ) administered intravenously during 2-5 min on days 1 and 8 of a 21-day cycle ) or treatment of physician 's choice ( TPC ) .\